ArticleBiomarker research2026
Emerging applications of long-read sequencing in hematological malignancies: highlights from the 2025 ASH annual meeting.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Long-read sequencing (LRS) is rapidly advancing and demonstrates considerable promise in hematological malignancies. At the 2025 ASH meeting, numerous studies highlighted advances in applying LRS across diverse hematological malignancies. Rapid LRS-based whole-genome sequencing and adaptive sampling enable real-time subtype assignment, detection of SNVs, CNVs, and gene fusions, as well as methylation-based classification. By spanning repetitive and structurally complex regions, LRS enhances genetic subtyping and uncovers clinically relevant structural variants often missed by short-read technologies. Full-length and single-cell RNA sequencing further resolve isoforms, splicing programs, and fusion transcripts within their clonal contexts, supporting precision therapy and refined risk stratification. As accuracy improves and costs decline, LRS is poised for broader integration into routine clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.